Drugs / COVID-19 Vaccine HIPRA
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05142514 | Nov → Dec 2021 | COVID-19 | Hipra Scientific, S.L.U | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | COVID-19 Vaccine HIPRA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05142514 ↗ |
| Modality | Vaccine | “Recombinant Protein RBD Fusion Dimer Candidate Vaccine” NCT05142514 ↗ |